(Q40738759)

23 September 2017

title

HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes (English)

1 reference

23 September 2017

author name string

Constantin N Baxevanis

1

1 reference

23 September 2017

Angelos D Gritzapis

2

1 reference

23 September 2017

Ourania E Tsitsilonis

3

1 reference

23 September 2017

Haralabos L Katsoulas

4

1 reference

23 September 2017

Michael Papamichail

5

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

International Journal of Cancer

23 September 2017

published in

1 reference

23 September 2017

volume

98

1 reference

23 September 2017

issue

6

1 reference

23 September 2017

page(s)

864-872

1 reference

Antigen presentation--recent developments

23 September 2017

cites work

1 reference

Human tumor antigens for cancer vaccine development

21 January 2018

1 reference

Human tumor antigens recognized by T cells

21 January 2018

1 reference

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

Human tumor antigens: implications for cancer vaccine development

21 January 2018

1 reference

Activated T cells and cytokine-induced CD3+CD56+ killer cells

21 January 2018

1 reference

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity

21 January 2018

1 reference

Generation and characterization of gp100 peptide-specific NK-T cell clones

21 January 2018

1 reference

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

21 January 2018

1 reference

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

21 January 2018

1 reference

Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201.

21 January 2018

1 reference

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.

21 January 2018

1 reference

Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses.

21 January 2018

1 reference

In situ T cells in melanoma

21 January 2018

1 reference

Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines

21 January 2018

1 reference

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

21 January 2018

1 reference

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor

21 January 2018

1 reference

Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones

21 January 2018

1 reference

Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer

21 January 2018

1 reference

Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha

21 January 2018

1 reference

The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.10251

1 reference

23 September 2017

1 reference